First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine

First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine

Bibliographic Details
Main Authors:	Fuchs JD, Frank I, Kochar N, Elizaga M, Allen M, Carter D, Frahm N, Kalams SA, Mulligan M, Sheets R, Pensiero M, Clarke D, Eldridge J
Format:	Article
Language:	English
Published:	BMC 2012-09-01
Series:	Retrovirology

Similar Items

Understanding the Spike Protein in COVID-19 Vaccine in Recombinant Vesicular Stomatitis Virus (rVSV) Using Automated Capillary Western Blots
by: Paul F. Gillespie, et al.
Published: (2023-01-01)

Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy
by: Suman Bishnoi, et al.
Published: (2018-02-01)

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
by: Thomas P. Monath, et al.
Published: (2019-04-01)

Development of Recombinant Oncolytic rVSV-mIL12-mGMCSF for Cancer Immunotherapy
by: Anastasia Ryapolova, et al.
Published: (2023-12-01)

Detectable vesicular stomatitis virus (VSV)–specific humoral and cellular immune responses following VSV–Ebola virus vaccination in humans
by: Poetsch, J, et al.
Published: (2018)

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
by: Agnandji, S, et al.
Published: (2016)

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
by: Agnandji, S, et al.
Published: (2016)

Evaluation of the immunogenicity and efficacy of an rVSV vaccine against Zika virus infection in macaca nemestrina
by: Jennifer Tisoncik-Go, et al.
Published: (2023-02-01)

Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization
by: Christine Dahlke, et al.
Published: (2017-05-01)

Prior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
by: Robert W. Cross, et al.
Published: (2020-07-01)

To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity
by: Amanda N. Pinski, et al.
Published: (2020-09-01)

Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?
by: Angela Huttner, et al.
Published: (2018-12-01)

The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs
by: Wenguang Cao, et al.
Published: (2023-06-01)

Recombinant Sudan virus and evaluation of humoral cross-reactivity between Ebola and Sudan virus glycoproteins after infection or rVSV-ΔG-ZEBOV-GP vaccination
by: Markus H. Kainulainen, et al.
Published: (2023-12-01)

Enhanced production yields of rVSV-SARS-CoV-2 vaccine using Fibra-Cel® macrocarriers
by: Noam Cohen, et al.
Published: (2024-02-01)

Development of an Integrated Continuous Manufacturing Process for the rVSV-Vectored SARS-CoV-2 Candidate Vaccine
by: Zeyu Yang, et al.
Published: (2023-04-01)

Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera
by: Yfat Yahalom-Ronen, et al.
Published: (2022-02-01)

Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?
by: Yuguo Zhang, et al.
Published: (2022-06-01)

Monitoring Viral Entry in Real-Time Using a Luciferase Recombinant Vesicular Stomatitis Virus Producing SARS-CoV-2, EBOV, LASV, CHIKV, and VSV Glycoproteins
by: Maria Fernanda Lay Mendoza, et al.
Published: (2020-12-01)

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV
by: Hiva Azizi, et al.
Published: (2023-05-01)

Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens
by: Anahita Fathi, et al.
Published: (2019-10-01)

Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge
by: Teresa E. Sorvillo, et al.
Published: (2021-08-01)

Development and scale-up of rVSV-SARS-CoV-2 vaccine process using single use bioreactor
by: Christopher Ton, et al.
Published: (2023-03-01)

Respuesta inmune humoral de una vacuna comercial contra la estomatitis vesicular en cerdos Humoral immune response induced by a commercial vaccine against vesicular stomatitis virus (VSV) in pigs
by: John J Arboleda, et al.
Published: (2005-08-01)

Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
by: Pejoski, D, et al.
Published: (2020)

Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice
by: Ian L. McWilliams, et al.
Published: (2019-02-01)

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
by: Anne Rechtien, et al.
Published: (2017-08-01)

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report.
by: Gsell, P, et al.
Published: (2017)

Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP
by: Eleonora Vianello, et al.
Published: (2023-12-01)

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
by: Huttner, A, et al.
Published: (2018)

Refined innate plasma signature after rVSVΔG-ZEBOV-GP immunization is shared among adult cohorts in Europe and North America
by: Paola Andrea Martinez-Murillo, et al.
Published: (2024-01-01)

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
by: Joan G. Tell, et al.
Published: (2020-12-01)

Synergistic antiviral activity of Lactobacillus acidophilus and Glycyrrhiza glabra against Herpes Simplex-1 Virus (HSV-1) and Vesicular Stomatitis Virus (VSV): experimental and In Silico insights
by: Dalia Elebeedy, et al.
Published: (2023-06-01)

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola
by: Jennifer K. Legardy-Williams, et al.
Published: (2020-03-01)

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.
by: Selidji T Agnandji, et al.
Published: (2017-10-01)

Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector
by: Ziteng Liang, et al.
Published: (2023-12-01)

Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cells
by: Hua-Long Xiong, et al.
Published: (2020-01-01)

Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
by: Eleonora Vianello, PhD, et al.
Published: (2022-02-01)

Growth, Antigenicity, and Immunogenicity of SARS-CoV-2 Spike Variants Revealed by a Live rVSV-SARS-CoV-2 Virus
by: Limin S. Ding, et al.
Published: (2022-01-01)

Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen
by: Joseph Jelinski, et al.
Published: (2023-12-01)